Evidence map›Paper›PMID 40614265›Full record

Observational studyJournal of neurosurgery2025

Identifying features of prior hemorrhage in cerebral cavernous malformations on quantitative susceptibility maps: a machine learning pilot study.

Serena Kinkade, Hui Li, Stephanie Hage, Janne Koskimäki, Agnieszka Stadnik, Justine Lee, Robert Shenkar, John Papaioannou, Kelly D Flemming, Helen Kim and 6 more

Registry-linked trialAbstract readObservational Study
In one paragraph

Observational study in Journal of neurosurgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03652181 (CASH), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03652181 completednot on this map

CASH (Cavernous Angiomas With Symptomatic Hemorrhage) Trial Readiness

TypeobservationalSponsorUniversity of ChicagoRan2018 to 2022Enrolled123ConditionsCCM, Cavernoma, Cerebral Cavernous Malformation, Cerebral Cavernous Malformations 1
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Serena Kinkade *Departments of1Neurological Surgery and.
Hui Li *2Diagnostic Radiology, University of Chicago Medicine and Biological Sciences, Chicago, Illinois.
Stephanie HageDepartments of1Neurological Surgery and.
Janne KoskimäkiDepartments of1Neurological Surgery and.
Agnieszka StadnikDepartments of1Neurological Surgery and.
Justine LeeDepartments of1Neurological Surgery and.
Robert ShenkarDepartments of1Neurological Surgery and.
John Papaioannou2Diagnostic Radiology, University of Chicago Medicine and Biological Sciences, Chicago, Illinois.
Kelly D Flemming3Department of Neurology, Mayo Clinic, Rochester, Minnesota.
Helen Kim4Department of Anesthesiology and Perioperative Care, University of California, San Francisco, California.
Michel Torbey5Department of Neurology, University of Oklahoma Health Sciences, Oklahoma City, Oklahoma; and.
Judy Huang6Department of Neurosurgery, Johns Hopkins University Medical Institutions, Baltimore, Maryland.
Timothy J Carroll2Diagnostic Radiology, University of Chicago Medicine and Biological Sciences, Chicago, Illinois.
Romuald GirardDepartments of1Neurological Surgery and.
Maryellen L Giger *2Diagnostic Radiology, University of Chicago Medicine and Biological Sciences, Chicago, Illinois.
Issam A Awad *Departments of1Neurological Surgery and.

Funding

Trial Readiness in Cavernous Angiomas with Symptomatic HemorrhageU01NS104157 · NINDS · UNIVERSITY OF CHICAGO · PI AWAD, ISSAM A · 2018 to 2022
$3.8M
NINDS NIH HHS U01 NS104157
6 · The paper itself

Abstract

Features of new bleeding on conventional imaging in cerebral cavernous malformations (CCMs) often disappear after several weeks, yet the risk of rebleeding persists long thereafter. Increases in mean lesional quantitative susceptibility mapping (QSM) ≥ 6% on MRI during 1 year of prospective surveillance have been associated with new symptomatic hemorrhage (SH) during that period. The authors hypothesized that QSM at a single time point reflects features of hemorrhage in the prior year or potential bleeding in the subsequent year. Twenty-eight features were extracted from 265 QSM acquisitions in 120 patients enrolled in a prospective trial readiness project, and machine learning methods examined associations with SH and biomarker bleed (QSM increase ≥ 6%) in prior and subsequent years. QSM features including sum variance, variance, and correlation had lower average values in lesions with SH in the prior year (p < 0.05, false discovery rate corrected). A support-vector machine classifier recurrently selected sum average, mean lesional QSM, sphericity, and margin sharpness features to distinguish biomarker bleeds in the prior year (area under the curve = 0.61, 95% CI 0.52-0.70; p = 0.02). No QSM features were associated with a subsequent bleed. These results provide proof of concept that machine learning may derive features of QSM reflecting prior hemorrhagic activity, meriting further investigation. Clinical trial registration no.: NCT03652181 (ClinicalTrials.gov).

Indexed as

Cerebral HemorrhageHemangioma, Cavernous, Central Nervous SystemMachine LearningAdultFemaleHumansMagnetic Resonance ImagingMaleMiddle AgedPilot ProjectsProspective StudiesYoung Adultbleedingcavernous malformationsdiagnostic techniquemagnetic resonance imagingquantitative susceptibilityvascular disorders

Identifiers

PMID40614265
PMCPMC12291556

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.